Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05257057 · ClinicalTrials.gov registry record
Frequency of Endometrial Cancer Precursors Associated with Lynch Syndrome
A clinical trial, sponsored by WellSpan Health.
- Completed
- Registry status
- 91
- Enrollment target
NCT05257057 is a clinical trial that has completed, run by WellSpan Health. The registered enrollment target is 91 participants.
The verdict
NCT05257057 has completed, sponsored by WellSpan Health.
- COMPLETED
- Registry status
- 91 participants
- Enrollment target
Study Summary
Given that there is a significant prevalence of Lynch syndrome among patients with endometrial cancer (about 5% of patients with endometrial cancer), and given there is a known risk of endometrial cancer among patients with endometrial hyperplasia (40% risk of pre-existing occult cancer with endometrial intraepithelial neoplasia), it is hypothesized that a diagnosis of endometrial hyperplasia may herald on-going risk of harboring a Lynch Syndrome gene mutation. The purpose of this study is to examine endometrial hyperplasia specimens and compare the frequency of Lynch Syndrome gene mutations between endometrial hyperplasia and endometrial cancer subjects. This will provide a rationale and opportunity for earlier screening, and reduce colon cancer morbidity and mortality secondary to the Lynch syndrome gene.
Interventions
- DIAGNOSTIC_TEST Immunohistochemical staining
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2019-05-08 |
| Est. Completion | 2023-06-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05257057
The ClinicalTrials.gov registry entry for NCT05257057 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is WellSpan Health, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immunohistochemical staining is the first listed.
NCT05257057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05257057 about?
NCT05257057 is a clinical study titled "Frequency of Endometrial Cancer Precursors Associated with Lynch Syndrome". Given that there is a significant prevalence of Lynch syndrome among patients with endometrial cancer (about 5% of patients with endometrial cancer), and given there is a known risk of endometrial cancer among patients with endometrial hyperplasia (40% risk of pre-existing occult cancer with endomet...
What is the current status of trial NCT05257057?
This trial is currently completed. The enrollment target is 91 participants. The study started on 2019-05-08. Estimated completion is 2023-06-02.
What interventions are being tested in trial NCT05257057?
The interventions under investigation include: Immunohistochemical staining (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05257057?
This trial is sponsored by WellSpan Health, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.